Search Results

Biognosys and Alamar Biosciences, Inc. are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers.

Biognosys, a leader in next-generation proteomics services, software and kits for life sciences research and drug development, announced the launch of the novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type enrichment with market leading performance and sensible, superior economics.

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced the operational readiness of its new proteomics facility in Massachusetts.

The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.

MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease in collaboration with the Biomarkers of Aging Consortium announced the launch of the next phase of the Biomarkers of Aging Challenge Series.

Sirona Biochem Corp. is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare’s newly published research report, “Novel Treatments for Age-Related Skin Problems.” The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market.